Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain
Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain
复制标题
DOI：
10.1016/s0264-410x(97)00081-9
复制
发表时间：
1997-10-01
期刊：
影响因子：
5.5
通讯作者：
Podesta, RB
中科院分区：
文献类型：
--
作者：
HotaMitchell, S;Siddiqui, AA;Podesta, RB
人类血吸虫感染，特别是曼氏血吸虫感染，每年在热带和亚热带地区占很大的发病率和死亡率。寄生虫的虫卵在受感染的宿主体内会引起病理变化；在慢性和重度感染中，这些变化可能会导致死亡。设计良好的抗血吸虫疫苗，单独或与现有的控制措施，如化疗，可能被证明是一种安全、廉价和有效的手段，以减少严重疾病的发生和死亡的曼氏血吸虫感染。以往的研究已经证明，含有曼氏血吸虫顶端质膜(APM)的合胞体对于寄生虫在哺乳动物宿主中的生存以及作为可能用作疫苗候选的免疫原的潜在来源都具有重要意义。在这篇文章中，我们提出了几种血吸虫抗原制剂的保护能力的证据，包括APM的钙结合蛋白，S.mansoni calain(GenBank登录号。M74233)。我们构建并鉴定了表达曼氏沙门氏菌Calain大亚基Sm-p80的重组杆状病毒。此重组Sm-p80可被感染曼氏血吸虫的人血清中的IgA、IgM、IgG1和IgG3同型抗体识别，部分纯化的重组Sm-p80可使感染曼氏血吸虫的免疫小鼠的虫量减少29-39%。我们的数据表明，Sm-p80可能是一种有用的疫苗抗原，可用于降低与哺乳动物宿主曼氏葡萄球菌感染相关的发病率。(C)1997年爱思唯尔科学有限公司。
Infections by human schistosomes, in particular Schistosoma mansoni, account for significant morbidity and mortality every year in tropical and sub-tropical areas. The eggs of the parasite induce pathological changes in the infected host; in chronic and heavy infections, these changes may lead to death. A well-designed anti-schistosomal vaccine, alone or in concert with existing control measures such as chemotherapy, may prove to be a safe, inexpensive, and effective means of reducing the occurrence of severe disease and death in S. mansoni infection. Previous studies have demonstrated the importance of the syncytial layer containing the apical plasma membrane (APM) of S. mansoni in both the survival of the parasite in the mammalian host and as a potential source of immunogens which may be utilized as vaccine candidates. In this paper, we present evidence for the protective capacity of several schistosomal antigen preparations, including a calcium binding protein of the APM, S. mansoni calpain (GenBank accession no. M74233). We have constructed and characterized expression of a recombinant baculovirus expressing the large subunit of S. mansoni calpain, Sm-p80. This recombinant Sm-p80 is recognized by IgA, IgM, IgG1, and IgG3 isotype antibodies found in S. mansoni-infected human sera and partially-purified recombinant Sm-p80 provided a 29-39% reduction in worm burden in immunized mice challenged with S. mansoni. Our data indicate that Sm-p80 may be a useful vaccine antigen for the reduction of the morbidity associated with S. mansoni infections of mammalian hosts. (C) 1997 Elsevier Science Ltd.